Journal article
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome
J Burn, DT Bishop, JP Mecklin, F Macrae, G Möslein, S Olschwang, ML Bisgaard, R Ramesar, D Eccles, ER Maher, L Bertario, HJ Jarvinen, A Lindblom, DG Evans, J Lubinski, PJ Morrison, JWC Ho, HFA Vasen, L Side, HJW Thomas Show all
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2008
Abstract
BACKGROUND: Observational and epidemiologic data indicate that the use of aspirin reduces the risk of colorectal neoplasia; however, the effects of aspirin in the Lynch syndrome (hereditary nonpolyposis colon cancer) are not known. Resistant starch has been associated with an antineoplastic effect on the colon. METHODS: In a randomized, placebo-controlled trial, we used a two-by-two design to investigate the effects of aspirin, at a dose of 600 mg per day, and resistant starch (Novelose), at a dose of 30 g per day, in reducing the risk of adenoma and carcinoma among persons with the Lynch syndrome. RESULTS: Among 1071 persons in 43 centers, 62 were ineligible to participate in the study, 72 ..
View full abstractGrants
Awarded by Medical Research Council
Funding Acknowledgements
Supported by Bayer, National Starch and Chemical, and grants from the U. K. Medical Research Council (G0100496), Cancer Research U. K. (C1297/A5013 and C588/A4994), the European Union (PL96/3694), the Cancer Council Victoria (Australia), The Technology and Human Resources for Industry Programme South Africa, and the Finnish Cancer Foundation. No potential conflict of interest relevant to this article was reported. We thank the participants in the CAPP2 study who agreed to undergo randomization and receive daily study agents for up to 4 years; Kirsi Pylvanainen (Jyvaskyla, Finland), Pascale Ives ( Melbourne, Australia), and Su Werner (Dusseldorf, Germany), our leading recruiters; and Pam Chapman, the project manager in its early stages.